Edition:
United Kingdom

Cara Therapeutics Inc (CARA.OQ)

CARA.OQ on NASDAQ Stock Exchange Global Market

23.30USD
13 Sep 2019
Change (% chg)

$0.29 (+1.26%)
Prev Close
$23.01
Open
$23.06
Day's High
$23.53
Day's Low
$22.79
Volume
239,404
Avg. Vol
243,745
52-wk High
$27.50
52-wk Low
$12.20

Latest Key Developments (Source: Significant Developments)

Cara Therapeutics Enters Into Commercial License Agreement With Enteris Biopharma For Peptelligence Oral Formulation Technology
Wednesday, 21 Aug 2019 

Aug 21 (Reuters) - Cara Therapeutics Inc ::CARA THERAPEUTICS ENTERS INTO COMMERCIAL LICENSE AGREEMENT WITH ENTERIS BIOPHARMA, INC. FOR PEPTELLIGENCE® ORAL FORMULATION TECHNOLOGY.CARA THERAPEUTICS INC - ENTERIS WILL RECEIVE AN UPFRONT PAYMENT OF $8 MILLION, INCLUDING $4 MILLION IN CASH AND $4 MILLION IN CARA COMMON STOCK.CARA THERAPEUTICS INC - ENTERIS IS ALSO ELIGIBLE TO RECEIVE DEVELOPMENT, REGULATORY AND TIERED COMMERCIAL MILESTONE PAYMENTS.CARA THERAPEUTICS INC - ENTERIS IS ALSO ELIGIBLE TO RECEIVE LOW, SINGLE-DIGIT ROYALTIES BASED ON NET SALES IN LICENSED TERRITORY.CARA THERAPEUTICS INC - RETAINS RIGHT TO BUY OUT ROYALTY OBLIGATION FOR A PERIOD OF TWO YEARS UNDER PRESPECIFIED CONDITIONS..CARA THERAPEUTICS - ENTERIS GRANTED CARA NON-EXCLUSIVE LICENSE TO ITS PEPTELLIGENCE TECHNOLOGY TO DEVELOP, COMMERCIALIZE ORAL KORSUVA WORLDWIDE.  Full Article

Cara Therapeutics Q2 Loss Per Share $0.58
Wednesday, 7 Aug 2019 

Aug 7 (Reuters) - Cara Therapeutics Inc ::CARA THERAPEUTICS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.58.Q2 EARNINGS PER SHARE ESTIMATE $-0.61 -- REFINITIV IBES DATA.TOTAL REVENUE OF $5.2 MILLION AND $2.9 MILLION FOR THREE MONTHS ENDED JUNE 30, 2019 AND 2018, RESPECTIVELY.  Full Article

Cara Therapeutics On July 8 Entered Into A Master Manufacturing Services Agreement With Patheon UK Ltd
Friday, 12 Jul 2019 

July 12 (Reuters) - Cara Therapeutics Inc ::CARA THERAPEUTICS INC - ON JULY 8, CO ENTERED INTO A MASTER MANUFACTURING SERVICES AGREEMENT WITH PATHEON UK LIMITED.CARA THERAPEUTICS INC - AGREED TO ORDER FROM PATHEON AT LEAST A CERTAIN PERCENTAGE OF ITS COMMERCIAL REQUIREMENTS FOR A PRODUCT.CARA THERAPEUTICS INC - MSA HAS AN INITIAL TERM ENDING DECEMBER 31, 2023.  Full Article

Cara Therapeutics Q1 Loss Per Share $0.56
Tuesday, 7 May 2019 

May 7 (Reuters) - Cara Therapeutics Inc ::CARA THERAPEUTICS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.56.Q1 REVENUE $4.4 MILLION.Q1 REVENUE ESTIMATE $3 MILLION -- REFINITIV IBES DATA.Q1 EARNINGS PER SHARE ESTIMATE $-0.58 -- REFINITIV IBES DATA.CARA THERAPEUTICS -SEES CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF MARCH 31,TO BE SUFFICIENT TO FUND OPERATING EXPENSES,CAPEX INTO Q4 2020.  Full Article

Cara Therapeutics Files For Mixed Shelf Offering Of Up To $300 Million - SEC Filing
Friday, 15 Mar 2019 

March 15 (Reuters) - Cara Therapeutics Inc ::CARA THERAPEUTICS FILES FOR MIXED SHELF OFFERING OF UP TO $300 MILLION - SEC FILING.  Full Article

Cara Therapeutics posts Q4 Loss Per Share of $0.52
Tuesday, 12 Mar 2019 

March 12 (Reuters) - Cara Therapeutics Inc ::CARA THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.52.Q4 EARNINGS PER SHARE ESTIMATE $-0.58 -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AT DECEMBER 31, 2018 TOTALED $182.8 MILLION.$5.5 MILLION OF LICENSE AND MILESTONE REVENUE DURING Q4.CARA THERAPEUTICS - EXPECTS CASH & CASH EQUIVALENTS, AVAILABLE-FOR-SALE MARKETABLE SECURITIES AS OF DECEMBER 31, 2018 SUFFICIENT TO FUND TILL 2021.  Full Article

Cara Therapeutics announces no modifications in trial size after completion of interim statistical assessment for kalm-1 phase 3 trial of Korsuva injection In Hemodialysis Patients With Pruritus
Wednesday, 2 Jan 2019 

Jan 2 (Reuters) - Cara Therapeutics Inc ::CARA THERAPEUTICS ANNOUNCES NO MODIFICATIONS IN TRIAL SIZE AFTER COMPLETION OF INTERIM STATISTICAL ASSESSMENT FOR KALM-1 PHASE 3 TRIAL OF KORSUVA INJECTION IN HEMODIALYSIS PATIENTS WITH PRURITUS.CARA THERAPEUTICS INC - TRIAL CONTINUES AS PLANNED WITH ENROLLMENT TARGET OF 350 PATIENTS.CARA THERAPEUTICS INC - TOP-LINE DATA READOUT FROM TRIAL EXPECTED IN FIRST HALF OF 2019.  Full Article

Cara Therapeutics Reports Q2 Loss Per Share Of $0.52
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - Cara Therapeutics Inc ::CARA THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.52.Q2 EARNINGS PER SHARE VIEW $-0.32 -- THOMSON REUTERS I/B/E/S.Q2 REVENUE $2.9 MILLION.  Full Article

Cara Therapeutics Announces Pricing Of $85.5 Mln Offering Of Common Stock
Thursday, 19 Jul 2018 

July 18 (Reuters) - Cara Therapeutics Inc ::CARA THERAPEUTICS ANNOUNCES PRICING OF $85.5 MILLION OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 4.50 MILLION COMMON SHARES PRICED AT $19.00PER SHARE.  Full Article

Cara Therapeutics Says Offering 4.50 Mln Common Shares
Tuesday, 17 Jul 2018 

July 17 (Reuters) - Cara Therapeutics Inc ::CARA THERAPEUTICS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK.SAYS OFFERING 4.50 MILLION COMMON SHARES.INTENDS TO USE NET PROCEEDS FROM UNDERWRITTEN OFFERING TO FUND ITS CLINICAL AND RESEARCH DEVELOPMENT ACTIVITIES.  Full Article